• properly identify and anticipate customer needs; • identify, retain, and manage third-party design and development firms, where appropriate, to accelerate development; • develop and introduce new products or services in a timely manner; • adequately protect our intellectual property and avoid infringing upon the intellectual property rights of third parties; • obtain and retain third-party licenses required for the development, commercialization, and/or utilization of new products; • demonstrate the safet ...

●● ..... ..... ●● CLEARPOINT® NEURO WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY." Nasdaq: CLPT November 2022 Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, the size of total addressable markets or the market opportunity for the Company's products and services, as well as management's expectations, beliefs, pl ...

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q3 2022 Earnings Conference Call November 8, 2022 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D’Alessandro - CFO Conference Call Participants William Wood - B. Riley Frank Takkinen - Lake Street Capital Operator Greetings, and welcome to the ClearPoint Neuro, Inc. Third Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A brief question-and-answer session will follow the formal presentation. [Operator In ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____to _____ Commission file number: 001-34822 ClearPoint Neuro, Inc. (Exact Name of Registran ...

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q2 2022 Earnings Conference Call August 9, 2022 4:30 PM ET Company Participants Joe Burnett - Chief Executive Officer Danilo D’Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital William Wood - B. Riley Operator Greetings, and welcome to the ClearPoint Neuro Second Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____to _____ Commission file number: 001-34822 ClearPoint Neuro, Inc. (Exact Name of Registrant as ...

●● ..... ..... ●● CLEARPOINT® NEURO WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY." Nasdaq: CLPT May 2022 Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of the ...

●● ..... ..... ●● CLEARPOINT® NEURO WHEN YOUR PATH IS UNCLEAR, WE POINT THE WAY." Nasdaq: CLPT May 2022 Statements herein concerning the Company's plans, growth and strategies may include forward-looking statements within the context of the federal securities laws. Statements regarding the Company's future events, developments and future performance, as well as management's expectations, beliefs, plans, estimates or projections relating to the future, are forward-looking statements within the meaning of the ...

ClearPoint Neuro, Inc. (NASDAQ:CLPT) Q1 2022 Earnings Conference Call May 11, 2022 4:30 PM ET Company Participants Joe Burnett - President & Chief Executive Officer Danilo D’Alessandro - Chief Financial Officer Conference Call Participants Frank Takkinen - Lake Street Capital Markets Marc Weisenberger - B. Riley Securities Operator Greetings and welcome to the ClearPoint Neuro, Inc. First Quarter 2022 Financial Results Conference Call. At this time, all participants are in a listen-only mode. A question-and ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Securities registered pursuant to Section 12(b) of the Act: FORM 10-Q (Mark One) þ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 Or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from_____to _____ Commission file number: 001-34822 ClearPoint Neuro, Inc. (Exact Name of Registrant as ...